Fig. 3

Proportion of patients with an increase or no change, mild decrease, or moderate/worse decrease in Hb level at month 6, with adjusted OR and 95% CI comparing IL-6Ri with TNFi and JAKi separately. *p < 0.001. The OR reported are from adjusted analyses. Adjusted model covariates were baseline Hb, age, duration of rheumatoid arthritis, morning stiffness duration, sex, current smoker status, prior use of one conventional synthetic disease-modifying anti-rheumatic drug, prior use of a non-TNFi biologic disease-modifying anti-rheumatic drug, white race, cyclic citrullinated peptide antibody positivity, and combination therapy with methotrexate. CI, confidence interval; Hb, hemoglobin; IL-6Ri, interleukin-6 receptor inhibitor; JAKi, Janus kinase inhibitor; OR, odds ratio; TNFi, tumor necrosis factor inhibitor